Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03166722
Other study ID # COSGOD Phase III
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 20, 2017
Est. completion date February 10, 2022

Study information

Verified date February 2022
Source Medical University of Graz
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the COSGOD Phase III trial is to examine, if it is possible to increase survival without cerebral injury in preterm neonates <32 weeks of gestation by monitoring the cerebral tissue oxygen saturation in addition to routine monitoring of arterial oxygen saturation and heart rate and specified clinical treatment guidelines during immediate transition period after birth (the first 15 minutes).


Description:

Background The transition to life after birth is a complex physiological process where the neonate has to establish sufficient ventilation and changes from intra-uterine circulation to extra-uterine circulation take place. During these processes the neonate has to provide the brain with adequate perfusion and oxygen delivery to maintain normal cerebral tissue oxygenation and activity. If hypoxia and bradycardia both common events during immediate transition in preterm neonates occur, cerebral hypoxia-ischaemia may cause perinatal brain injury that is the major causes of mortality and long term neurodevelopmental impairment. Objectives The primary objective of the COSGOD Phase III trial is to examine, if it is possible to increase survival without cerebral injury in preterm neonates <32 weeks of gestation by monitoring the cerebral tissue oxygen saturation in addition to routine monitoring of arterial oxygen saturation (SpO2) and heart rate (HR) and specified clinical treatment guidelines during immediate transition period after birth (the first 15 minutes). Hypothesis The investigators hypothesise that using cerebral tissue oxygen saturation in addition to SpO2 and HR monitoring and specified treatment guidelines during immediate transition and resuscitation would increase survival without cerebral injury in preterm neonates. Trial design An investigator-initiated randomised, multi-centre, multinational, phase III clinical trial involving preterm infants from European countries and North America. Inclusion and exclusion criteria The inclusion criteria are: neonates born more than 8 weeks preterm (gestational age up to 31 weeks and 6 days); decision to conduct full life support; parental informed consent; and cerebral NIRS oximeter placed within three minutes after birth. Sample size According to actual data of two European centres (Graz and Rotterdam) and one Canadian centre (Edmonton) the percentage of neonates not affected by mortality and cerebral injury is 65%. Assuming an increase of not affected neonates from 65% to 75% and a dropout rate of 10% a total of 724 neonates are required to detect this difference with a two group χ² test (alpha: 0.05, power: 80%). Intervention The premature infants will be randomised into experimental or control group. Both groups will have a near infrared spectroscopy (NIRS) device (left frontal), pulse-oximeter (right wrist) and electrocardiogram placed within three minutes after birth. In the study group, the cerebral tissue saturation, SpO2 and HR readings are visible, and the infant will be treated accordingly using a defined treatment guideline. In the control group, only SpO2 and HR will be visible, and the infant will be treated according routine treatment. Duration of intervention Monitoring will be started within 3 minutes after birth and the intervention will last during immediate transition period and resuscitation up to 15 minutes after birth. Follow up Thereafter, each neonate will be followed up for primary outcome to term date or discharge. Outcome measures The primary outcome is mortality and/or cerebral injury defined as any intraventricular bleeding and/or cystic periventricular leucomalacia. The secondary outcomes are neonatal morbidities.


Recruitment information / eligibility

Status Completed
Enrollment 655
Est. completion date February 10, 2022
Est. primary completion date January 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 15 Minutes
Eligibility Inclusion Criteria: - Preterm neonates less than completed 32 weeks, - Decision to conduct full life support, - Written informed consent. Exclusion Criteria: - No decision to conduct full life support, - No written informed consent, - Congenital malformation.

Study Design


Intervention

Other:
Control group
SpO2 and HR monitoring and routine treatment during immediate transition
Device:
Study group
Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring

Locations

Country Name City State
Austria Department of Pediatrics, Medical University of Graz Graz Styria
Austria Medical University Innsbruck Innsbruck
Austria Medical University Vienna Vienna
Canada Royal Alexandra Hospital Edmonton Alberta
Germany Universitätsklinikum Freiburg Freiburg
Germany Centre for Pediatric Clinical Studies Tübingen
Ireland University College Cork Cork
Italy Ospedale dei Bambini "V.Buzzi" Milano Milano
Italy Institute for Maternal and Child Health, IRCCS Burlo Garofolo Trieste
Poland Poznan University of Medical Sciences Poznan
Poland Uniwersytetu Medycznego im. Karola Marcinkowskiego Poznan
Slovenia University Medical Centre Ljubljana Ljubljana

Sponsors (2)

Lead Sponsor Collaborator
Medical University of Graz Royal Alexandra Hospital

Countries where clinical trial is conducted

Austria,  Canada,  Germany,  Ireland,  Italy,  Poland,  Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality and/or occurrence of cerebral injury Number of patients, who die or have intraventricular hemorrhage or have periventricular leucomalacia up to 19 weeks after birth
Secondary Frequency of neonatal morbidities Number of patients, who have infection and/or sepsis and/or necrotizing enterocolitis bronchoplumonary dysplasia, retinopathia prematurorumand/or bronchoplumonary dysplasia and /or retinopathia prematurorum up to 19 weeks after birth
Secondary Sex Number of male and female patients, who die or have intraventricular hemorrhage or have periventricular leucomalacia up to 19 weeks after birth
Secondary Gestational age Number of patients with less than 28 weeks of gestation and more than or equal 28 weeks of gestation, who die or have intraventricular hemorrhage or have periventricular leucomalacia up to 19 weeks after birth
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05542108 - Adding Motion to Contact: A New Model for Low-cost Family Centered Very-early Onset Intervention in Very Preterm-born Infants N/A
Completed NCT03400904 - Extubation Strategies in Neuro-Intensive Care Unit Patients and Associations With Outcome.
Completed NCT06073145 - Transcranial Doppler Using Wearable Ultrasound Patch
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Recruiting NCT06010823 - Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants N/A
Not yet recruiting NCT05833568 - Five-day 20-minute 10-Hz tACS in Patients With a Disorder of Consciousness N/A
Withdrawn NCT04288076 - The Brain and Lung Interaction (BALI) Study N/A
Not yet recruiting NCT02756585 - Computed Tomography Perfusion in Patients With Severe Head Injury N/A
Completed NCT03162484 - Physical Activity and Chronic Acquired Brain Injury N/A
Terminated NCT01430988 - Observational Study of the BrainScope® Ahead™ M-100 in UK Emergency Department Patients With Head Injury N/A
Completed NCT01093053 - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations N/A
Completed NCT00975338 - The LETS Study: A Longitudinal Evaluation of Transition Services
Completed NCT00878631 - Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline Phase 2/Phase 3
Not yet recruiting NCT04478812 - Tbit System Precision and Correlation of Different Blood Samples N/A
Recruiting NCT05443542 - VIrtual Reality in Cognitive Rehabilitation of Processing Speed for Persons With ABI N/A
Recruiting NCT05309005 - Virtual Reality and Social Cognition After Acquired Brain Injury
Completed NCT02702635 - Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging N/A
Withdrawn NCT04247321 - Non-invasive Near-infrared Spectroscopy (NIRS) Versus Invasive Licox Intracranial Pressure N/A
Not yet recruiting NCT04386525 - Omega 3 and Ischemic Stroke; Fish Oil as an Option Phase 4
Completed NCT03636399 - Group Based Treatment for Persons With Social Communication Difficulties N/A